018221797

ÆTERNA ZENTARIS

---

April 2, 2020

Trademark Summary

The trademark application ÆTERNA ZENTARIS was filed by AEterna Zentaris GmbH, a corporation established under the laws of the Federal Republic of Germany (the "Applicant"). The application was published for oppositions on May 3, 2020, and it was registered by office on August 10, 2020 without any oppositions.

The application was filed in English (German was selected as the second language).

Change of name and professional address of the trademark registration was recorded on May 13, 2020.

---

Goods And Services

• The mark was filed in class 5 with following description of goods:
  
  1. Pharmaceutical preparations used for the treatment of cancer
  2. Pharmaceutical preparations administered as a radiosensitizer and used for the treatment of cancer
  3. Pharmaceutical preparations used for the treatment of urological diseases
  4. Pharmaceutical preparations used for the treatment of hormonal disorders
  5. Peptides containing pharmaceutical preparations used for hormonal and tumors treatments
  6. Pharmaceutical preparations used for the treatment of endocrine diseases
  7. Pharmaceutical preparations used for the treatment of carcinoid tumors
  8. Pharmaceutical preparations used for the treatment of haematological diseases
  9. Pharmaceutical preparations used for the treatment of age-related diseases
  10. Pharmaceutical preparations used for the treatment of ophthalmological disorders
  11. Pharmaceutical preparations used for the treatment of reproductive system disorders
  12. Pharmaceutical preparations used for the treatment of endometriosis
  13. Pharmaceutical preparations used for the treatment of uterine myoma
  14. Pharmaceutical preparations used for the treatment of non-malignant tumors
  15. Pharmaceutical preparations used for the treatment of benign prostatic hyperplasia (BPH)
  16. Pharmaceutical preparations used for the treatment of tropical diseases
  17. Pharmaceutical preparations used for the treatment of infectious disease
  18. Pharmaceutical preparations used for the treatment of leishmaniasis
  19. Pharmaceutical preparations used for the treatment of obesity
  20. Pharmaceutical preparations used for the treatment of diabetes and disorders related to diabetes
  21. Pharmaceutical preparations containing cytotoxic products (conjugated or not)
  22. Pharmaceutical preparations used as a tubulin inhibitor
  23. Pharmaceutical preparations based on LHRH antagonists platform
  24. Pharmaceutical preparations based on bombesin antagonist platform
  25. Pharmaceutical preparations based on inhibitors of the Akt pathway
  26. Pharmaceutical preparations based on angiogenesis inhibitors platform
  27. Pharmaceutical preparations used to induce apoptosis
  28. Pharmaceutical preparations used to stimulate growth hormone secretagogue (GHS)
  29. Tumor vaccines
  30. Pharmaceutical preparations for the treatment of cardiovascular diseases
  31. Preparations for the treatment of respiratory diseases
  32. Pharmaceutical preparations for the treatment of gastrointestinal diseases
  33. Diagnostic agents
  34. Pharmaceutical products for the treatment of neurological disorders
  35. Pharmaceutical preparations for the treatment of nasopharyngeal disorders
  36. Antibiotics
  37. Antibacterial and fungicidal preparations
  38. Pharmaceutical preparations for the treatment of mental health
  39. Pharmaceutical preparations for the treatment of autoimmune diseases
  40. Pharmaceutical preparations for the treatment of rheumatoid diseases
  41. Pharmaceutical preparations for contraceptives and women's health
  42. Analgesic pharmaceutical products
  43. Sedativa and pharmaceutical preparations for the treatment of psychiatric disorders
  44. Pharmaceutical preparations for the treatment of pain
  45. Pharmaceutical preparations for palliative treatments
  46. Pharmaceutical preparations for the treatment of addictions
  47. Pharmaceutical formulations for the treatment of paediatric indications.